满足肿瘤成像未来临床与诊断需求:成纤维细胞活化蛋白靶向成像结构化报告系统FAP-RADS 1.0版
本文提出FAP-RADS 1.0版框架,用于标准化成纤维细胞活化蛋白(FAP)靶向成像的报告。该系统基于文献综述与核医学专家共识、参照分子影像RADS原则设计,采用5点评分评估病灶恶性可能性,不依赖SUV阈值,适用于多种FAP PET与FAP SPECT示踪剂及不同肿瘤类型,旨在改善临床沟通并支持多中心研究。
要点
- FAP-RADS 1.0版采用5点评分评估病灶恶性可能性,基于病灶影像特征。
- 该系统不依赖SUV阈值,可适用于药代动力学不同的多种FAP配体。
- 系统不限定成像模态(FAP PET与FAP SPECT)和示踪剂化合物结构。
核心结论
- 所提出的FAP-RADS 1.0版是一个全面且灵活的框架,有潜力提升临床实践中FAP靶向成像判读的质量与一致性。
- 其应用可能带来更好的研究结局、更广泛的肿瘤学界接受度,并简化FAP放射性示踪剂审批相关的监管流程。
研究设计与样本
- 本研究通过全面文献综述,并结合核医学专家共识,基于分子影像RADS框架原则设计新的评分系统。
- FAP-RADS 1.0版旨在适用于多种肿瘤类型及不同放射性示踪剂摄取模式,不限定成像模态(FAP PET与FAP SPECT)和放射性示踪剂化合物结构。
主要发现
- FAP-RADS 1.0版引入5点评分,基于病灶影像特征评估病灶恶性可能性。
- 该评分系统可应用于药代动力学不同的多种FAP配体。
- 该框架不依赖SUV阈值,使其在临床使用中具有灵活性和稳健性。
- 该系统的实施旨在改善跨学科沟通、支持纵向随访并促进未来多中心试验。
关键数值与推荐
- FAP-RADS 1.0版采用5点评分评估病灶恶性可能性。
- 该评分系统不依赖SUV阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein (FAP)-targeted imaging has emerged as a promising diagnostic tool for various oncologic and nononcologic conditions. However, the increasing employment of FAP-targeted imaging with small-molecule radiotracers mandates a standardized reporting system to ensure consistent interpretation across various clinical scenarios, especially in oncologic imaging. This study proposes an FAP reporting and data system (RADS) framework (FAP-RADS version 1.0) to address those needs, aiming to standardize FAP-targeted imaging reports, improve clinical communication, and support multicenter research. Methods: We conducted a comprehensive literature review and combined the findings with expert consensus in nuclear medicine to design a new scoring system based on the principles of the molecular imaging RADS framework. FAP-RADS version 1.0 is intended for use across multiple tumor types with variable radiotracer uptake patterns and is nonspecific to imaging modality (FAP PET and FAP SPECT) and radiotracer compound structure. We aimed to ensure that the system would be user-friendly and applicable to routine clinical practice. Results: FAP-RADS version 1.0 introduces a 5-point scale to assess the likelihood of malignancy in lesions based on the imaging characteristics of the lesions. The scoring system can be applied to different FAP ligands with varying pharmacokinetics. The framework does not rely on SUV thresholds, making it flexible and robust for clinical use. The implementation of this system aims to improve interdisciplinary communication, support longitudinal follow-up, and facilitate future multicenter trials. Conclusion: The proposed FAP-RADS version 1.0 is a comprehensive and flexible framework that has the potential to enhance the quality and consistency of FAP-targeted imaging interpretation in clinical practice. Its application may lead to better research outcomes, broader acceptance within the oncologic community, and streamlined regulatory processes related to FAP-based radiotracer approval.
引用
- Novruzov E, Sheikh GT, Mamlins E, et al. Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein-Targeted Imaging-FAP-RADS Version 1.0. J Nucl Med. 2025. PMID: 40473461. doi:10.2967/jnumed.125.269914
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。